FDA Approval for New Dry Eye Drug Granted
Sun Pharma reports that it has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first
and only approved CsA product that incorporates a nanomicellar technology.
“Dry Eye Disease represents an area of high unmet medical need, with a significant number of
patients who are currently untreated,” said Abhay Gandhi, CEO, North America, Sun Pharma.
“The U.S. FDA approval of CEQUA represents a long-awaited dry eye treatment option and is an
important milestone in the development of Sun’s Ophthalmics business. CEQUA, with its novel
nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear
Click HERE for the full press release.